| 发明名称 |
Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation |
| 摘要 |
A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed. |
| 申请公布号 |
US9301957(B2) |
申请公布日期 |
2016.04.05 |
| 申请号 |
US201414273874 |
申请日期 |
2014.05.09 |
| 申请人 |
Novartis AG |
发明人 |
Bhardwaj Upkar;Comfort Ann Reese;Li Ping;Li Shoufeng;Makarov Alexey;Bordawekar Mangesh Sadashiv |
| 分类号 |
A61K31/506;A61K9/28 |
主分类号 |
A61K31/506 |
| 代理机构 |
|
代理人 |
Houghton Gregory |
| 主权项 |
1. A solid dosage form comprising: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed 4-15 minutes, and wherein 7-13% of the solid dosage form is the polymer that coats the core. |
| 地址 |
Basel CH |
